Quantcast

Stonepine Capital Management, LLC Buys Viveve Medical Inc, Avadel Pharmaceuticals PLC, ...


Shutterstock photo
Stonepine Capital Management, LLC
  • New Purchases: AVDL , EBS , XOMA , VNDA,
  • Added Positions:VIVE, OPHT, SCLN, VCEL, CPIX, DRRX, BDSI, NVLN, AVIR,
  • Reduced Positions:ALR, VCYT, ALIM, ENTA, CRME, TRIB,
  • Sold Out:SCMP, MNK, CUTR, JNP,

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonepine+Capital+Management%2C+LLC

These are the top 5 holdings of Stonepine Capital Management, LLC

  1. Recro Pharma Inc ( REPH ) - 2,874,317 shares, 15.3% of the total portfolio.
  2. Viveve Medical Inc ( VIVE ) - 3,849,711 shares, 14.77% of the total portfolio. Shares added by 48.08%
  3. Novelion Therapeutics Inc ( NVLN ) - 1,560,487 shares, 10.21% of the total portfolio. Shares added by 2.39%
  4. SciClone Pharmaceuticals Inc ( SCLN ) - 1,663,281 shares, 9.93% of the total portfolio. Shares added by 33.15%
  5. Ophthotech Corp ( OPHT ) - 3,516,489 shares, 7.84% of the total portfolio. Shares added by 53.36%


New Purchase: Avadel Pharmaceuticals PLC (AVDL)

Stonepine Capital Management, LLC initiated holdings in Avadel Pharmaceuticals PLC. The purchase prices were between $9.15 and $11.57, with an estimated average price of $10. The stock is now traded at around $10.14. The impact to the portfolio due to this purchase was 4.44%. The holdings were 752,410 shares as of 2017-03-31.

New Purchase: Emergent BioSolutions Inc (EBS)

Stonepine Capital Management, LLC initiated holdings in Emergent BioSolutions Inc. The purchase prices were between $28.36 and $34.66, with an estimated average price of $30.44. The stock is now traded at around $31.53. The impact to the portfolio due to this purchase was 0.96%. The holdings were 54,505 shares as of 2017-03-31.

New Purchase: XOMA Corp (XOMA)

Stonepine Capital Management, LLC initiated holdings in XOMA Corp. The purchase prices were between $4.03 and $7.14, with an estimated average price of $5.14. The stock is now traded at around $6.48. The impact to the portfolio due to this purchase was 0.38%. The holdings were 87,960 shares as of 2017-03-31.

New Purchase: Vanda Pharmaceuticals Inc (VNDA)

Stonepine Capital Management, LLC initiated holdings in Vanda Pharmaceuticals Inc. The purchase prices were between $13.05 and $15.95, with an estimated average price of $14.25. The stock is now traded at around $14.45. The impact to the portfolio due to this purchase was 0.37%. The holdings were 43,300 shares as of 2017-03-31.

Added: Viveve Medical Inc ( VIVE )

Stonepine Capital Management, LLC added to the holdings in Viveve Medical Inc by 48.08%. The purchase prices were between $3.99 and $6.33, with an estimated average price of $4.86. The stock is now traded at around $7.81. The impact to the portfolio due to this purchase was 4.8%. The holdings were 3,849,711 shares as of 2017-03-31.

Added: Ophthotech Corp ( OPHT )

Stonepine Capital Management, LLC added to the holdings in Ophthotech Corp by 53.36%. The purchase prices were between $3.28 and $5.13, with an estimated average price of $4.23. The stock is now traded at around $2.58. The impact to the portfolio due to this purchase was 2.73%. The holdings were 3,516,489 shares as of 2017-03-31.

Added: SciClone Pharmaceuticals Inc ( SCLN )

Stonepine Capital Management, LLC added to the holdings in SciClone Pharmaceuticals Inc by 33.15%. The purchase prices were between $9.4 and $10.85, with an estimated average price of $9.99. The stock is now traded at around $9.75. The impact to the portfolio due to this purchase was 2.47%. The holdings were 1,663,281 shares as of 2017-03-31.

Added: Vericel Corp (VCEL)

Stonepine Capital Management, LLC added to the holdings in Vericel Corp by 73.34%. The purchase prices were between $2.5 and $3.1, with an estimated average price of $2.83. The stock is now traded at around $2.65. The impact to the portfolio due to this purchase was 2.36%. The holdings were 3,265,323 shares as of 2017-03-31.

Added: Durect Corp (DRRX)

Stonepine Capital Management, LLC added to the holdings in Durect Corp by 28.63%. The purchase prices were between $0.91 and $1.37, with an estimated average price of $1.07. The stock is now traded at around $1.28. The impact to the portfolio due to this purchase was 0.4%. The holdings were 2,801,376 shares as of 2017-03-31.

Sold Out: Sucampo Pharmaceuticals Inc (SCMP)

Stonepine Capital Management, LLC sold out the holdings in Sucampo Pharmaceuticals Inc. The sale prices were between $10.25 and $13.95, with an estimated average price of $11.61.

Sold Out: Mallinckrodt PLC (MNK)

Stonepine Capital Management, LLC sold out the holdings in Mallinckrodt PLC. The sale prices were between $42.54 and $54.74, with an estimated average price of $49.35.

Sold Out: Cutera Inc (CUTR)

Stonepine Capital Management, LLC sold out the holdings in Cutera Inc. The sale prices were between $17.45 and $21.9, with an estimated average price of $19.73.

Sold Out: Juniper Pharmaceuticals Inc (JNP)

Stonepine Capital Management, LLC sold out the holdings in Juniper Pharmaceuticals Inc. The sale prices were between $4.6 and $5.75, with an estimated average price of $5.05.



Premium Members

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: REPH , VIVE , NVLN , OPHT



More from GuruFocus

Subscribe






GuruFocus
Contributor:

GuruFocus

Stock Picks, Portfolios










Research Brokers before you trade

Want to trade FX?